pharm l2s4 28june2010

Page 1 sur 1 1 Evaluation: Pharmacology –UY1/FMSB/PHCL200-L2S4 28june2010 : ---- 55mins Section A: Multiple Choice Questions (Choose the ONE best answer) 1. After how many pharmacokinetics half-lives could you estimate the percentage of drug removed from the body to be greater than 97%? [a] 2 [b] 3 [c] 4 [d] 5 [e] 6 2. What is the volume of distribution of a drug that gives a plasma concentration of 0.1mg/ml after giving a 1 gram dose by Intra-venous bolus? [a] 10 litres [b] 1 litre [c] 1000 litres [d] 10000 litres [e] 0.1 litre 3. What characteristic(s) could make an adverse drug reaction to be considered as serious? [a] An adverse drug reaction that results in congenital malformation [b] An adverse drug reaction that results in death [c] An adverse drug reaction that results in hospitalisation [d] An Adverse drug reaction that results in disability [e] All of the above 4. Which of the following adverse effects could be described as Type D (Delayed)? [a] Phocomelia caused by thalidomide [b] Aplastic anemia caused by chloramphenicol [c] Gastro-intestinal bleeding caused by aspirine [d] Dry mouth caused by anti-cholinergic [e] Insomia caused by caffeine Figure 1: Curve of relative concentration of ligand versus fraction of maximal binding / cellular response of a new drug C2342 (for question 5- 6 refer to figure 1) 5. The relative concentration of ligand of value A represents which of the following? [a] Css [b] Cmax [c] ED50 [d] Ka [e] LD50 6. The relative concentration of ligand of value B represents which of the following? [a] Css [b] Cmax [c] ED50 [d] Ka [e] LD50 Figure 2: Concentration-time curve cure of the new drug C2342 (including various pharmacokinetic parameters P1,P2, P3, P4, AUC, MEC- Minimum effect concentration; MT C-minimum therapeutic concentration) (Refer to Figure 2 for questions 7- 10) 7. Which of the above parameters represents time period for the duration of action of drug? [a] P1 [b] P2 [c] P3 [d] P4 [e] AUC 8. Which of the above parameters represents Cmax [a] P1 [b] P2 [c] P3 [d] P4 [e] AUC 9. Which of the above parameters represents Tmax [a] P1 [b] P2 [c] P3 [d] P4 [e] AUC 10. Which of the above parameters represents the Time of onset of drug action [a] P1 [b] P2 [c] P3 [d] P4 [e] AUC Section B: OPEN Questions 11. List the risk factors that predispose a patient to adverse drug reactions? (4pts) 12. Give the limitations of clinical trials as concerns the detection of adverse drug reactions. (3pts) 13. Cite 2 organ dysfunctions and their respective mechanisms that could cause variable plasma concentrations of drugs (2pts) 14. Cite 2 mechanisms of drug interaction at the level of absorption as concerns oral administration of drugs (2pts) P1 A B P2 P3 P4

Upload: safemind

Post on 04-Apr-2018

216 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

7/29/2019 pharm L2S4 28june2010

http://slidepdf.com/reader/full/pharm-l2s4-28june2010 1/1

Page 1 sur 1

Evaluation: Pharmacology –UY1/FMSB/PHCL200-L2S4 28june2010 : ---- 55mins Section A: Multiple Choice Questions (Choose the ONE best answer)

1. After how many pharmacokinetics half-lives could you estimate the percentage of drug removed fromthe body to be greater than 97%?

[a] 2[b] 3[c] 4[d] 5[e] 6

2. What is the volume of distribution of a drug that gives a plasma concentration of 0.1mg/ml after giving a1 gram dose by Intra-venous bolus?

[a] 10 litres

[b] 1 litre[c] 1000 litres[d] 10000 litres[e] 0.1 litre

3. What characteristic(s) could make an adverse drug reaction to be considered as serious?[a] An adverse drug reaction that results in congenital malformation[b] An adverse drug reaction that results in death[c] An adverse drug reaction that results in hospitalisation[d] An Adverse drug reaction that results in disability[e] All of the above

4. Which of the following adverse effects could be described as Type D (Delayed)?[a] Phocomelia caused by thalidomide[b] Aplastic anemia caused by chloramphenicol[c] Gastro-intestinal bleeding caused by aspirine

[d] Dry mouth caused by anti-cholinergic[e] Insomia caused by caffeine

Figure 1: Curve of relative concentration of ligand versus fraction of maximal binding / cellular response of a new drug C2342 (for question 5- 6 refer to figure 1)

5. The relative concentration of ligand of value A represents which of the following?[a] Css[b] Cmax[c] ED50[d] Ka[e] LD50

6. The relative concentration of ligand of value B represents which of the following?[a] Css[b] Cmax[c] ED50[d] Ka[e] LD50

Figure 2: Concentration-time curve cure of the new drug C2342 (including various pharmacokinetic parameters P1,P2, P3, P4, AUC, MEC- Minimum effect concentration; MTC-minimum therapeutic concentration)

(Refer to Figure 2 for questions 7- 10)

7. Which of the above parameters represents time period for the duration of action of drug?

[a] P1[b] P2[c] P3

[d] P4[e] AUC

8. Which of the above parameters represents Cmax[a] P1[b] P2[c] P3[d] P4[e] AUC

9. Which of the above parameters represents Tmax[a] P1[b] P2

[c] P3[d] P4

[e] AUC

10. Which of the above parameters represents the Time of onset of drug action[a] P1[b] P2[c] P3[d] P4[e] AUC

Section B: OPEN Questions

11. List the risk factors that predispose a patient to adverse drug reactions? (4pts)

12. Give the limitations of clinical trials as concerns the detection of adverse drug reactions. (3pts)